Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY20 results · Apr–Jun 2019
Bliss GVS Pharma reported revenue from operations of ₹211.53 crore (up 3.0% from Q1 FY19) and net profit of ₹33.37 crore (down 14.4% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 211.53 | 205.33 | +3.0% | 244.05 | −13.3% |
| Other income | 2.11 | 13.87 | −84.8% | 2.79 | −24.3% |
| Total income | 213.64 | 219.20 | −2.5% | 246.84 | −13.4% |
| Profit before tax | 47.41 | 51.04 | −7.1% | 31.60 | +50.0% |
| Net profit for the period | 33.37 | 38.98 | −14.4% | 18.79 | +77.6% |
| Attributable to shareholders of the company | 33.79 | 38.32 | −11.8% | 18.11 | +86.6% |
| EPS, basic (₹) | 3.28 | 3.72 | −11.8% | 1.76 | +86.4% |
| Net margin (%) | 15.8 | 19.0 | 7.7 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 115.16 | 104.84 | +9.8% | 106.14 | +8.5% |
| Other income | 1.79 | 13.14 | −86.4% | 3.02 | −40.6% |
| Total income | 116.95 | 117.98 | −0.9% | 109.16 | +7.1% |
| Profit before tax | 36.11 | 37.68 | −4.1% | 14.86 | +143.0% |
| Net profit for the period | 23.92 | 27.05 | −11.6% | 4.64 | +415.6% |
| EPS, basic (₹) | 2.32 | 2.62 | −11.5% | 0.45 | +415.6% |
| Net margin (%) | 20.8 | 25.8 | 4.4 |
Consolidated
- Filed with BSE
- 13 Aug 2019, 17:48 IST
- Board meeting
- 12 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2019, 17:48 IST
- Board meeting
- 12 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE